{
    "medicine_id": "348a01d0e30becf96c8b098f8c42dee0ba8fbf43",
    "platform_id": "DB06261",
    "metadata": {
        "name": "Cysview 100 mg 50mL Kit",
        "composition": "100 mg 50mL Hexaminolevulinate",
        "clinical_particulars": {
            "therapeutic_indications": "Hexaminolevulinate is indicated for use in the cystoscopic detection of non muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion s on the basis of a prior cystoscopy",
            "contraindications": {
                "disease": "No studies in animals have been conducted to evaluate the carcinogenic potential of hexaminolevulinate hydrochloride Hexaminolevulinate hydrochloride was not mutagenic in in vitro reverse mutation tests in bacteria or in chromosome aberration tests in human peripheral blood lymphocytes and was negative in an in vivo micronucleus test in mice after intravenous injection of doses up to 45 mg kg in the absence of light activation Adequate studies have not been performed to evaluate the genetic toxicity of hexaminolevulinate hydrochloride in the presence of light activation Adequate reproductive and developmental toxicity studies in animals have not been performed to evaluate the effects of hexaminolevulinate hydrochloride on fertility",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In vitro studies have shown increased porphyrin fluorescence in normal urothelium after exposure to hexaminolevulinate hydrochloride intravesical solution In the human bladder a greater accumulation of porphyrins is proposed in neoplastic or inflamed cells compared to normal urothelium After bladder instillation of hexaminolevulinate hydrochloride intravesical solution for approximately 1 hour and subsequent illumination with blue light at wavelengths 360 450nm the porphyrins will fluoresce red",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00707",
                        "description": "Hexaminolevulinate may increase the photosensitizing activities of Porfimer sodium"
                    },
                    {
                        "drugbank-id": "DB00460",
                        "description": "Hexaminolevulinate may increase the photosensitizing activities of Verteporfin"
                    },
                    {
                        "drugbank-id": "DB12768",
                        "description": "BCG vaccine may decrease effectiveness of Hexaminolevulinate as a diagnostic agent"
                    },
                    {
                        "drugbank-id": "DB00755",
                        "description": "The risk or severity of adverse effects can be increased when Tretinoin is combined with Hexaminolevulinate"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}